NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved the PD-L1 (SP142) Assay developed by Roche subsidiary Ventana as a complementary diagnostic for Genentech's PD-L1 inhibitor Tecentriq, which was recently approved to treat lung cancer.

The complementary assay, while not required for the safe and effective use of Tecentriq, can determine patients' PD-L1 expression levels, which in turn "can provide insight into the survival benefit that may be achieved" with treatment, Roche said in a statement today. The test gauges PD-L1 expression in tumor and immune cells.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Jul
24
Sponsored by
Qiagen

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms. 

Aug
09

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.